Omeros Co. (NASDAQ:OMER) traded up 0.5% during trading on Thursday . The stock traded as high as $10.65 and last traded at $10.58. 375,471 shares changed hands during trading, a decline of 67% from the average session volume of 1,134,810 shares. The stock had previously closed at $10.63.
Several equities research analysts have commented on the company. Needham & Company LLC lowered Omeros from a “buy” rating to a “hold” rating and set a $9.01 price target for the company. in a research note on Friday, March 2nd. HC Wainwright set a $30.00 price target on Omeros and gave the stock a “buy” rating in a research note on Monday, March 5th. Maxim Group set a $24.00 price target on Omeros and gave the stock a “buy” rating in a research note on Friday, March 2nd. ValuEngine lowered Omeros from a “sell” rating to a “strong sell” rating in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald set a $19.00 price target on Omeros and gave the stock a “hold” rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $28.75.
The company has a debt-to-equity ratio of -29.93, a quick ratio of 4.10 and a current ratio of 4.12.
Several hedge funds have recently bought and sold shares of OMER. C M Bidwell & Associates Ltd. acquired a new stake in shares of Omeros in the fourth quarter valued at about $106,000. First Interstate Bank acquired a new stake in Omeros during the 3rd quarter valued at approximately $108,000. Cypress Capital Group acquired a new stake in Omeros during the 4th quarter valued at approximately $194,000. Hanseatic Management Services Inc. grew its stake in Omeros by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 10,592 shares in the last quarter. Finally, Malaga Cove Capital LLC acquired a new stake in Omeros during the 4th quarter valued at approximately $242,000. Institutional investors and hedge funds own 48.77% of the company’s stock.
WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3253104/omeros-omer-trading-0-5-higher.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.